Replimune (REPL) EBIT (2017 - 2026)

Replimune has reported EBIT for 10 years, with the latest figure at -$73.3 million in Q1 2026.

• Quarterly EBIT rose 7.55% year-over-year to -$73.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319.9 million (down 22.28% YoY) and the FY2026 annual result came in at -$319.9 million, down 22.28% from the prior year.
• EBIT eased to -$73.3 million in Q1 2026 per REPL's latest filing, from -$71.9 million in the prior quarter.
• Over five years, EBIT peaked at -$32.0 million in Q1 2022 and troughed at -$90.4 million in Q2 2025.
• A 5-year average of -$60.3 million and a median of -$58.8 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2023 and 2024: EBIT plunged 65.67% in 2023, then rose 7.7% in 2024.
• Over 5 years, EBIT stood at -$41.6 million in 2022, then sank by 35.82% to -$56.5 million in 2023, then dropped by 16.77% to -$66.0 million in 2024, then retreated by 8.86% to -$71.9 million in 2025, then fell by 2.05% to -$73.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$73.3 million, -$71.9 million, and -$84.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.